The shares of MannKind Corporation (NASDAQ:MNKD) currently has mean rating of 3.2 while 0 analyst have recommended the shares as ‘BUY’ ,1 recommended as ‘OUTPERFORM’ and 1 recommended as ‘HOLD’.The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell
The mean price target for the shares of MannKind Corporation (NASDAQ:MNKD) is at $1.43 while the highest price target suggested by the analysts is $4.00 and low price target is $0.10. The mean price target is calculated keeping in view the consensus of 3 brokerage firms.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 30.00K by 4 analysts. The means estimate of sales for the year ending Dec 16 is 3.78M by 4 analysts.
The average estimate of EPS for the current fiscal quarter for MannKind Corporation (NASDAQ:MNKD) stands at $-0.06 while the EPS for the current year is fixed at $-0.24 by 3.00 analysts
The next one year’s EPS estimate is set at -0.25 by 3.00 analysts while a year ago the analysts suggested the company’s EPS at $-0.24. The analysts also projected the company’s long-term growth at 26.80% for the upcoming five years
In its latest quarter ended on 31 Mar 2016 , MannKind Corporation (NASDAQ:MNKD) reported earnings of $-0.06. The posted earnings missed the analyst’s consensus by $-0.02 with the surprise factor of -50.00%. In the matter of earnings surprises, the term ‘Cockroach Effect’ is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
MannKind Corporation (NASDAQ:MNKD) traded up +2.88% during trading on Friday, hitting $1.07 . The stock had a trading volume of 2.9 M shares. The firm has a 50 day moving average of $1.04 and a 200-day moving average of $1.24. The stock has a market cap of $459.20M. On Jun 25, 2015 the shares registered one year high at $5.97 and the one year low was seen on Jan 6, 2016.
On June 12, 2016 MannKind Corporation (NASDAQ:MNKD) announced results of two late-breaking posters and four additional analyses of Afrezza® (insulin human) Inhalation Powder, including three posters demonstrating a faster onset of action and a shorter duration than rapid-acting insulin analogs in patients with diabetes mellitus. These data were presented at the American Diabetes Association’s 76th Scientific Sessions (ADA). Afrezza, approved by the FDA in 2014 to improve glycemic control in adult patients with type 1 and type 2 diabetes mellitus, is the only inhaled insulin product available in the U.S.
A randomized, controlled, six-treatment, crossover dose-response study (Poster #100-LB) comparing Afrezza to the rapid-acting insulin analog, Lispro, in 30 patients with type 1 diabetes was presented as a late-breaking poster. Results for doses matched to provide the same GIR-AUC (activity parameter) demonstrated:
- Onset of action within 16 to 21 minutes for Afrezza compared to 45 to 52 minutes for subcutaneous insulin across studies
- Afrezza’s duration of action at clinically relevant doses was consistently shorter by 2 to 3 hours
- Afrezza’s labeled dose overestimates its effect reinforcing the need for appropriate dose titration
Similar results were presented in Poster# 975-P and in a separate meta-analysis of three open-label clamp trials (Poster #931-P) comparing the onset of action of Afrezza with that of subcutaneous Lispro or regular human insulin, which showed onset of action (time to 10% GIR-AUC 0-240) with Afrezza was faster at 25 to 34 minutes compared to 53 to 60 minutes with Lispro.
These data highlight the faster onset of action of Afrezza compared with subcutaneous insulins is relevant for optimal dosing, and supports Afrezza’s use for rapidly controlling elevated glucose levels.
Many people with type 1 diabetes and progressed type 2 diabetes inject rapid-acting insulin analogs to address rising blood sugar levels caused by food.i Hypoglycemia, a dangerous condition that occurs when blood sugar levels drop too low, can be a concern when the effects of rapid-acting insulin analogs extend past mealtime and food absorption. Insulin-related hypoglycemia resulted in nearly 100,000 hospital visits per year in the U.S. between 2007 and 2011, with a cost of $600 million during that five-year period.ii
“When administering an inhaled rapid-acting insulin or an injectable rapid-acting insulin analog, it is critical to strike the balance of providing prandial glucose control while minimizing the risk for post-prandial hypoglycemic events,” said Raymond W. Urbanski, MD, PhD, Chief Medical Officer of MannKind. “These data show Afrezza begins to work in the body more rapidly and leaves the bloodstream more quickly than an injectable rapid-acting insulin analog, which could translate into more flexibility in the timing of administration and a lower potential for hypoglycemic episodes following meals.”